Clinical Trial Update: A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

Phase III clinical trial update for Penpulimab in relapsed and refractory classical Hodgkin's lymphoma (NCT05244642).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Penpulimab

Snippet

Sponsor: Akeso | Conditions: Hodgkin Disease Lymphoma | Phase 3 | Status: UNKNOWN